Actigraphic assessment of sleep quality in the A4 trial

 描述(由申请人提供)：抗淀粉样蛋白治疗无症状阿尔茨海默病(A4)家长试验是一项针对1000名认知健康、年龄在65-85岁之间、在FLOBETAPIR PET扫描中有淀粉样蛋白证据的参与者进行的预防Cognitiv下降的抗淀粉样蛋白治疗试验。睡眠质量对生活质量很重要，有证据表明老年人和阿尔茨海默病高危人群的睡眠质量较差。肌动记录仪是一种低成本、非侵入性的活动测量方法，可用于评估睡眠质量，它使用的是像手表一样佩戴的加速度计。我们建议在同意A4的50名淀粉样阳性和50名淀粉样阴性参与者中增加睡眠质量的动态评估。我们希望评估抗淀粉样蛋白治疗对睡眠质量的影响，以及在安慰剂和淀粉样蛋白阴性组中，基线淀粉样蛋白状态对睡眠变化的影响。

 DESCRIPTION (provided by applicant): The Anti-Amyloid Treatment of Asymptomatic Alzheimer's Disease (A4) parent trial is a trial of anti-amyloid therapy for prevention of cognitiv decline in 1000 participants who are cognitively healthy, 65-85 years old, and have evidence of amyloid in their brain on flobetapir PET scans. Quality of sleep is important for quality of life ad there is evidence for poorer sleep quality in older persons and in persons at risk of developing Alzheimer's disease. Actigraphy is a low-cost noninvasive method of measuring activity validated for assessing sleep quality, using an accelerometer that is worn like a wristwatch. We propose to add actigraphic assessment of sleep quality in 50 amyloid-positive and 50 amyloid-negative participants who have consented to A4. We hope to assess the effect of anti-amyloid therapy on sleep quality, and the effect of baseline amyloid status on changes in sleep in the placebo and amyloid-negative group.